Additional cytogenetic alterations in TCP-ALL include fusion genes encoding chimeric oncogenic proteins, such as SIL-TAL1 and MLL, which, in some studies, have been associated with favorable clinical outcomes [17]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.